Twin Health Raises $140M Series C to Scale Its Groundbreaking Whole Body Digital Twin™ Service Enabling Reversal and Prevention of Chronic Metabolic Disease

Whole Body Digital Twin™ is a dynamic digital representation of each person’s metabolism – a powerful confluence of cutting-edge technology and advanced medical science, providing precise guidance to enable reversal and prevention of chronic metabolic disease

Twin Health, makers of the Whole Body Digital Twin™ precision health service, today announced $140 million in Series C funding as it scales its service in the U.S. and globally.

Founded in 2018, Twin Health invented the Whole Body Digital Twin™ to help reverse and prevent chronic metabolic diseases, while improving energy and physical health. Powered by artificial intelligence, the Whole Body Digital Twin™ is a dynamic representation of each individual’s unique metabolism, built from thousands of data points collected daily via non-invasive wearable sensors and self-reported preferences. The Whole Body Digital Twin™ is a predictive model that provides individualized nutrition, sleep, activity and breathing guidance to patients and their healthcare providers, helping to reverse and prevent multiple chronic metabolic diseases.

“We are each gifted a body. If given a chance, it can heal itself. Our Whole Body Digital Twin™ lives alongside you – giving you a view into your beautifully complex biology, continuously learning about your metabolism and telling you what you can do to improve your health in the moment,” said Jahangir Mohammed, Founder and CEO of Twin Health.

Chronic metabolic disease is widespread and growing. The global prevalence of Metabolic Syndrome is estimated as 20-25%. Worldwide, 415 million people are living with diabetes, and more than 500 million will have diabetes by 2040, according to the CDC.

Chronic metabolic diseases, such as type 2 diabetes, can start as an individual’s metabolism breaks down over time. Medical research has demonstrated that each person’s metabolism functions uniquely, presenting significant challenges to healthcare providers’ understanding and ability to customize treatment for every single person. For the first time, the Whole Body Digital Twin™ addresses this complexity using cutting-edge technology and advanced medical science to deliver personalized, precise and timely insights with recommendations to address the root cause.

Twin Health’s service is an all-inclusive program consisting of multiple sensors including continuous glucose monitors and fitness watches, comprehensive blood tests and the development of each member’s individualized Whole Body Digital Twin™, as well as consultations with healthcare providers and Twin coaches. The Whole Body Digital Twin™ technology continuously monitors the health of the individual and enables healthcare providers and Twin coaches to take quick actions. Through an easy-to-use app, patients and their care team are provided individualized, precise, timely guidance across nutrition, sleep, activity and breathing. Healthcare providers can access organized biomarker data and medication reduction recommendations for their patients, with the goal of reversing chronic disease. The Twin service is available today via partner programs such as employer benefits or health insurance plans.

Twin Health’s clinical research team is conducting the world’s first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology. Early RCT data were recently presented and published in the American Diabetes Association’s Diabetes journal, with first of its kind health outcomes. Patients had an average HbA1c reduction of 3.1 (average baseline 8.7) with over 90% achieving type 2 diabetes reversal (HbA1c less than 6.5), and 92% eliminating all diabetes medications including insulin. Furthermore, patients had an average weight reduction of 9.1 kg (20 lbs). Among patients with baseline abnormal liver function (as defined by an elevated ALT on clinical lab values) there was an average ALT reduction of 24 units/L. In comparison, the control group did not achieve diabetes reversal, any reduction in diabetes medications, or a significant improvement in weight or liver function. The scientific outcomes from the RCT and the commercial results have been published in 13 peer-reviewed international medical journals and conference papers and abstracts.

“The Whole Body Digital Twin™ is delivering a new standard of care, empowering physicians and patients to make highly personalized data-driven decisions based on real-time feedback coming from patients’ own bodies,” said Dr. Toby Cosgrove, Executive Advisor/Cleveland Clinic, who is on Twin Health’s board of directors.

Used as early as the 1960s, digital twin technology is at a new inflection point, applied across sectors ranging from auto to aircraft and energy thanks to advances in sensor technology, connectivity, and the computing power required to machine learn with massive volumes of data. Through application of this advanced technology to one of the most complex systems of all – the human metabolism – Twin Health is addressing the root cause of chronic metabolic disease.

Company founder Jahangir Mohammed is a serial inventor, entrepreneur and tech pioneer with early successes in mobile connectivity, the Internet of Things and digital twin technology. He founded Kineto Wireless in 2000, pioneering the use of WiFi technologies in mobile phones for indoor voice and data. He later founded and built Jasper Technologies into a leading global IoT platform, acquired by Cisco for $1.4B in 2016.

“The Whole Body Digital Twin™ became my life’s work after my eyes were opened to the magnitude of chronic disease globally. I had seen too many loved ones impacted by the daily challenges of living with these diseases, forever changing the futures they imagined,” said Mohammed, who initially bootstrapped the company, and self-funded $10 million. “The impact the Twin service has had on our members’ lives energizes and inspires me, hearing their stories as they begin to understand the intricacies of their own metabolism and feel empowered to heal from the inside out.”

The Series C funding round includes ICONIQ Growth, Sequoia Capital India, Perceptive Advisors, Corner Ventures, LTS Investments, Helena and Sofina, enabling Twin Health to scale its Whole Body Digital Twin™ service and help solve the chronic metabolic disease health crisis.

“We are delighted to partner with the visionary Jahangir Mohammed and his exceptional team as they scale Twin Health and its groundbreaking technology to address one of the biggest healthcare challenges of our time,” said Divesh Makan, founding partner of ICONIQ. “Twin Health has the opportunity to transform and improve the quality of life for so many people, and we are incredibly proud to support the company’s mission.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.